National Health Investors stock
NHINYSENational Health Investors, Inc., Real EstateISIN US63633D1046
60Score 60 out of 100, Neutral
Price and trend
36 / 100
Price history
−15% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 15% below it.
Since June 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 42).
The price is 29% below its 52-week high. Largest decline in 20 years: 63% (February 2020 to March 2020).
Chart figures for advanced users
- SMA 50$67.47
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$75.90
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)42
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$63.96
- The lowest closing price of the last twelve months.
- Resistance$91.02
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- National Health Investors, Inc. belongs to the REIT (Healthcare Facilities) industry (United States) and, with a market value of $3.17B, is number 10 of 18 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $378.53M (up 12.9% year on year) and earnings of $142.18M (up 3%).
- MEQIRI Score 60 out of 100 (Neutral): rank 94 of 325 in Real Estate, median 55.
Show more
- The P/E is 4.6 (REIT (Healthcare Facilities) median 14.5, own median of recent years 22.4).
- For real estate investment trusts (REITs) what counts is funds from operations (FFO and AFFO). The P/E and the payout ratio of earnings say little here, because depreciation on properties depresses earnings.
- Our model puts fair value at $87.90, with the price 27% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 100% over the last 12 months, REIT (Healthcare Facilities) median 6.6%.Profitability 79
- Modestly valuedP/E 4.6, REIT (Healthcare Facilities) median 14.5, own median 22.4.Valuation 96
- Below fair valuePrice 27% below the fair value of $87.90.Valuation 96
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are valuation and profitability, while momentum and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 61 to 60.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- calm price action
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $73.25 and expensive above $109.87 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $99.28 (cash-flow model) and $76.52 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $79.59, at 7.8% it would be $100.36.
Valuation metrics
Half from the cash-flow model, half from FFO per share times the median price to FFO of the REIT industry (16.6). For REITs, depreciation on buildings depresses earnings, so FFO counts instead of earnings, here following the industry rule (Nareit) from the filings with the SEC: gains on property sales are deducted where the company reports them in the standard items. The cash-flow model uses AFFO: operating cash flow less maintenance, estimated at 4% of revenue, and less preferred dividends. New construction and acquisitions do not count as running costs there.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 28.6% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 37%, operating 51%, net 38%. Last 12 months: net 100%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 9 Nov 2026EPS reported $11.47 (expected $1.18)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $3.890.0%
- Revenue
- $281.61M0.0%
- Earnings per share
- $3.22−0.3%
- Revenue
- $279.04M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.6%Outlook unchanged: results in line with plan, same-store SHOP NOI growth of 1% to 3%, cash G&A guidance unchanged.
“Farrell Granath: For the full year, 1% to 3% range for the same-store SHOP NOI growth relative to the same-store SHOP NOI, which were more in the negative range or below the midpoint of that guidance in the first half of the year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $167,027 in total.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at National Health Investors
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
325 rated companies in Real Estate
- This company
- 60
- Sector median
- 55
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in REIT (Healthcare Facilities)
The next larger and next smaller companies by market value
- CareTrust REITCTRE $9.83B67
- Healthcare Realty TrustHR $6.65B46
- AedificaAED.BR $6.1B62
- Sabra Health Care REITSBRA $5.39B50
- LTC PropertiesLTC $2.46B71
- Diversified Healthcare TrustDHC $1.77B32
- National Healthcare Properties, Inc. (NHP)NHP $1.11B40
- Medical Properties TrustMPT $1.02B40
ETFs that hold National Health Investors
Held by 20 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| UBS FTSE EPRA Nareit Developed Green UCITS ETF USD disCSYZ | 0.51% | 0.25% | €207.65M |
| iShares US Property Yield UCITS ETFIQQ7 | 0.29% | 0.40% | €556.83M |
| State Street SPDR Dow Jones Global Real Estate UCITS ETF (Dist)SPYJ | 0.20% | 0.40% | €331.25M |
Show 5 more
| iShares Developed Markets Property Yield UCITS ETFIQQ6 | 0.20% | 0.59% | €813.1M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.18% | 0.30% | €2.31B |
| Amundi FTSE EPRA NAREIT Global UCITS ETF Dist10AJ | 0.17% | 0.24% | €606.07M |
| HSBC FTSE EPRA NAREIT Developed UCITS ETFH4ZL | 0.17% | 0.24% | €3.37B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.15% | 0.30% | €185.82M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Jan 2023)
- Valuation signal Undervalued since 11 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.